Compare AJANTA PHARMA with Suven Life Sciences - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs SUVEN LIFE SCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA SUVEN LIFE SCIENCES AJANTA PHARMA/
SUVEN LIFE SCIENCES
 
P/E (TTM) x 27.6 -80.7 - View Chart
P/BV x 6.8 1.3 538.8% View Chart
Dividend Yield % 0.5 1.8 28.5%  

Financials

 AJANTA PHARMA   SUVEN LIFE SCIENCES
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
SUVEN LIFE SCIENCES
Mar-19
AJANTA PHARMA/
SUVEN LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,422338 421.1%   
Low Rs898169 529.9%   
Sales per share (Unadj.) Rs233.552.1 447.9%  
Earnings per share (Unadj.) Rs44.06.8 643.6%  
Cash flow per share (Unadj.) Rs52.28.6 608.5%  
Dividends per share (Unadj.) Rs9.001.50 600.0%  
Dividend yield (eoy) %0.80.6 131.2%  
Book value per share (Unadj.) Rs255.165.3 390.7%  
Shares outstanding (eoy) m88.02127.28 69.2%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.04.9 102.1%   
Avg P/E ratio x26.437.1 71.1%  
P/CF ratio (eoy) x22.229.6 75.2%  
Price / Book Value ratio x4.53.9 117.1%  
Dividend payout %20.522.0 93.2%   
Avg Mkt Cap Rs m102,08132,272 316.3%   
No. of employees `0006.81.1 628.5%   
Total wages/salary Rs m4,307661 651.4%   
Avg. sales/employee Rs Th3,022.66,132.2 49.3%   
Avg. wages/employee Rs Th633.4611.1 103.7%   
Avg. net profit/employee Rs Th569.1803.5 70.8%   
INCOME DATA
Net Sales Rs m20,5546,635 309.8%  
Other income Rs m211242 87.0%   
Total revenues Rs m20,7656,877 301.9%   
Gross profit Rs m5,6641,604 353.1%  
Depreciation Rs m721221 325.6%   
Interest Rs m1238 30.8%   
Profit before tax Rs m5,1431,587 324.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,273718 177.3%   
Profit after tax Rs m3,870869 445.1%  
Gross profit margin %27.624.2 114.0%  
Effective tax rate %24.845.2 54.7%   
Net profit margin %18.813.1 143.7%  
BALANCE SHEET DATA
Current assets Rs m11,8126,232 189.5%   
Current liabilities Rs m3,7761,490 253.4%   
Net working cap to sales %39.171.5 54.7%  
Current ratio x3.14.2 74.8%  
Inventory Days Days7786 89.5%  
Debtors Days Days8283 98.8%  
Net fixed assets Rs m14,3984,043 356.1%   
Share capital Rs m175127 137.8%   
"Free" reserves Rs m22,2778,183 272.2%   
Net worth Rs m22,4528,310 270.2%   
Long term debt Rs m718 37.1%   
Total assets Rs m26,96210,389 259.5%  
Interest coverage x444.343.1 1,030.8%   
Debt to equity ratio x00 13.7%  
Sales to assets ratio x0.80.6 119.4%   
Return on assets %14.48.7 164.9%  
Return on equity %17.210.5 164.7%  
Return on capital %23.019.5 117.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,6825,622 190.0%   
Fx outflow Rs m2,1021,799 116.8%   
Net fx Rs m8,5803,822 224.5%   
CASH FLOW
From Operations Rs m3,748356 1,054.2%  
From Investments Rs m-2,228-279 799.7%  
From Financial Activity Rs m-1,475-225 655.1%  
Net Cashflow Rs m45-148 -30.5%  

Share Holding

Indian Promoters % 73.8 63.4 116.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 0.0 -  
FIIs % 7.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 36.5 46.6%  
Shareholders   20,968 37,287 56.2%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   WYETH  IPCA LABS  JUBILANT LIFE SCIENCES  NEULAND LABS  PIRAMAL ENTERPRISES  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls Over 750 Points from Day's High; Metal and Realty Stocks Witness Selling(Closing)

After opening the day on a strong note, Indian share markets witnessed a sharp sell-off during closing hours today and ended lower.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 60.8% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 60.8% YoY). Sales on the other hand came in at Rs 7 bn (up 34.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 21, 2021 03:30 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS